ABUS short interest
Arbutus Biopharma Corp · Healthcare · Biotechnology · settlement date 2026-09-30
| Shares short | 34,053,358 |
|---|---|
| Change vs prior report | 15,568,448 (+84.2%) |
| Change over six months | +110.5% |
| Days to cover | 3.53 (sector: 3.78) |
| Average daily volume | 9,652,199 |
| Rank in Healthcare | #583 of 922 by days to cover |
ABUS short interest, last 12 months
| Settlement | Shares short | Change | Days to cover | Avg daily volume |
|---|---|---|---|---|
| 2026-09-30 | 34,053,358 | +84.2% | 3.53 | 9,652,199 |
| 2026-09-15 | 18,484,910 | -2.3% | 5.01 | 3,691,181 |
| 2026-08-31 | 18,916,119 | +2.5% | 3.08 | 6,139,181 |
| 2026-08-14 | 18,456,085 | -8.8% | 15.10 | 1,222,134 |
| 2026-07-31 | 20,236,241 | +3.0% | 13.69 | 1,478,060 |
| 2026-07-15 | 19,653,287 | +14.8% | 7.40 | 2,655,278 |
| 2026-06-30 | 17,111,453 | -2.4% | 4.89 | 3,499,322 |
| 2026-06-15 | 17,522,670 | +3.2% | 13.96 | 1,255,250 |
| 2026-05-29 | 16,982,764 | +3.3% | 9.18 | 1,849,722 |
| 2026-05-15 | 16,438,082 | -7.4% | 17.08 | 962,486 |
| 2026-04-30 | 17,743,389 | -0.3% | 7.17 | 2,476,388 |
| 2026-04-15 | 17,803,913 | +10.1% | 11.44 | 1,556,792 |
| 2026-03-31 | 16,174,093 | -1.4% | 7.04 | 2,297,163 |
| 2026-03-13 | 16,405,599 | +11.2% | 4.18 | 3,927,055 |
| 2026-02-27 | 14,756,509 | -1.6% | 9.52 | 1,550,244 |
| 2026-02-13 | 14,998,521 | +10.6% | 6.43 | 2,334,202 |
| 2026-01-30 | 13,558,940 | +3.8% | 7.47 | 1,815,351 |
| 2026-01-15 | 13,067,041 | +4.2% | 12.17 | 1,073,545 |
| 2025-12-31 | 12,535,638 | +16.7% | 8.63 | 1,451,951 |
| 2025-12-15 | 10,740,954 | -4.2% | 9.28 | 1,156,866 |
| 2025-11-28 | 11,206,745 | +6.1% | 9.87 | 1,135,178 |
| 2025-11-14 | 10,563,698 | +6.5% | 10.74 | 983,752 |
| 2025-10-31 | 9,916,540 | +0.5% | 10.35 | 958,117 |
| 2025-10-15 | 9,863,869 | -2.7% | 10.52 | 937,420 |
| 2025-09-30 | 10,136,672 | -9.2% | 9.56 | 1,060,185 |
import finzdata as yf
yf.Ticker("ABUS").short_interest # every report since 2017
yf.Client().short_interest(["ABUS"], start="2018-01-01")Healthcare short interest · ABUS price history · Who owns ABUS · All short interest